INTRODUCTION: Rodent disease models can play an indispensable role in drug development. Confirming that translationally-relevant disease mechanisms are engaged in such models is a crucial facet of this process. Accordingly, we have validated the role of calcitonin gene-related peptide signaling in a mouse model of glyceryl trinitrate-provoked migraine-like pain and a spontaneous rat model of migraine-like pain by assessing their pharmacological responsiveness to the small molecule calcitonin gene-related peptide receptor antagonist olcegepant, and the humanised monoclonal calcitonin gene-related peptide antibody ALD405. METHODS: Cutaneous sensitivity to hind paw, and periorbital mechanical stimulation were used as surrogate markers of activation of relevant pain pathways in each respective model. Separate experiments were performed to identify the time-course of treatment response to olcegepant (1 mg/kg i.p.) and ALD405 (10 mg/kg i.p.). RESULTS: Olcegepant and ALD405 significantly alleviated cutaneous mechanical hypersensitivity in both models compared with corresponding control treatments (saline and IgG control antibody respectively). As expected, the duration of anti-nociceptive action obtained with ALD405 was considerably longer than that associated with olcegepant. Surprisingly, in the spontaneous rat model the onset of action of ALD405 occurred within just 4 hours after administration. DISCUSSION: The current data clearly show that calcitonin gene-related peptide-mediated signaling is critically involved in the manifestation of cutaneous hypersensitivity in distinct rodent models of migraine-like pain and emphasise their translational relevance. Moreover, the unexpected rapidity of onset observed for ALD405 supports i) a probable site of action outside the blood-brain barrier, and ii) a potential clinical utility of specific monoclonal calcitonin gene-related peptide antibodies in the abortive treatment of migraine.
INTRODUCTION: Rodent disease models can play an indispensable role in drug development. Confirming that translationally-relevant disease mechanisms are engaged in such models is a crucial facet of this process. Accordingly, we have validated the role of calcitonin gene-related peptide signaling in a mouse model of glyceryl trinitrate-provoked migraine-like pain and a spontaneous rat model of migraine-like pain by assessing their pharmacological responsiveness to the small molecule calcitonin gene-related peptide receptor antagonist olcegepant, and the humanised monoclonal calcitonin gene-related peptide antibody ALD405. METHODS: Cutaneous sensitivity to hind paw, and periorbital mechanical stimulation were used as surrogate markers of activation of relevant pain pathways in each respective model. Separate experiments were performed to identify the time-course of treatment response to olcegepant (1 mg/kg i.p.) and ALD405 (10 mg/kg i.p.). RESULTS:Olcegepant and ALD405 significantly alleviated cutaneous mechanical hypersensitivity in both models compared with corresponding control treatments (saline and IgG control antibody respectively). As expected, the duration of anti-nociceptive action obtained with ALD405 was considerably longer than that associated with olcegepant. Surprisingly, in the spontaneous rat model the onset of action of ALD405 occurred within just 4 hours after administration. DISCUSSION: The current data clearly show that calcitonin gene-related peptide-mediated signaling is critically involved in the manifestation of cutaneous hypersensitivity in distinct rodent models of migraine-like pain and emphasise their translational relevance. Moreover, the unexpected rapidity of onset observed for ALD405 supports i) a probable site of action outside the blood-brain barrier, and ii) a potential clinical utility of specific monoclonal calcitonin gene-related peptide antibodies in the abortive treatment of migraine.
Authors: Katarzyna M Targowska-Duda; Akihiko Ozawa; Zachariah Bertels; Andrea Cippitelli; Jason L Marcus; Hanna K Mielke-Maday; Gilles Zribi; Amanda N Rainey; Brigitte L Kieffer; Amynah A Pradhan; Lawrence Toll Journal: Neuropharmacology Date: 2020-03-06 Impact factor: 5.250
Authors: Zachariah Bertels; Harinder Singh; Isaac Dripps; Kendra Siegersma; Alycia F Tipton; Wiktor D Witkowski; Zoie Sheets; Pal Shah; Catherine Conway; Elizaveta Mangutov; Mei Ao; Valentina Petukhova; Bhargava Karumudi; Pavel A Petukhov; Serapio M Baca; Mark M Rasenick; Amynah A Pradhan Journal: Elife Date: 2021-04-15 Impact factor: 8.140
Authors: Candler Paige; Isabel Plasencia-Fernandez; Moeno Kume; Melina Papalampropoulou-Tsiridou; Louis-Etienne Lorenzo; Eric T David; Lucy He; Galo L Mejia; Christopher Driskill; Francesco Ferrini; Andrew L Feldhaus; Leon F Garcia-Martinez; Armen N Akopian; Yves De Koninck; Gregory Dussor; Theodore J Price Journal: J Neurosci Date: 2022-01-20 Impact factor: 6.709
Authors: Tarique Benbow; Felisha Teja; Afrooz Sheikhi; Fernando G Exposto; Peter Svensson; Brian E Cairns Journal: Sci Rep Date: 2022-08-16 Impact factor: 4.996
Authors: Tobias Gluexam; Alexander M Grandits; Angela Schlerka; Chi Huu Nguyen; Julia Etzler; Thomas Finkes; Michael Fuchs; Christoph Scheid; Gerwin Heller; Hubert Hackl; Nathalie Harrer; Heinz Sill; Elisabeth Koller; Dagmar Stoiber; Wolfgang Sommergruber; Rotraud Wieser Journal: Int J Mol Sci Date: 2019-11-20 Impact factor: 5.923